Supplemental material

The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia – a post-hoc analysis of a Phase 3, single-arm, open-label trial

C Stefanutti¹, DJ Blom², MR Averna³ EA Meagher⁴, H dT Theron⁵, AD Marais⁵, RA Hegele⁶, CR Sirtori⁷, PK Shah⁸, D Gaudet⁹, GB Vigna¹⁰, BS Sachais,⁶ S Di Giacomo,¹ AME du Plessis¹¹, LT Bloedon¹², J Balser¹³, DJ Rader⁴ and M Cuchel⁴ for the Phase 3 HoFH Lomitapide Study Investigators

¹’Sapienza’ University of Rome, Roma, Italy, ²University of Cape Town, Cape Town, South Africa, ³Università di Palermo, Palermo, Italy, ⁴University of Pennsylvania, Philadelphia, PA, USA, ⁵Netcare Private Hospital, Bloemfontein, South Africa, ⁶Robarts Research Institute and University of Western Ontario, London, ON, Canada, ⁷Ospedale Niguarda, Milano, Italy, ⁸Cedars–Sinai Heart Institute, Los Angeles, CA, USA, ⁹Université de Montreal, Chicoutimi, Canada, ¹⁰Università di Ferrara, Ferrara, Italy, ¹¹University of Pretoria, South Africa, ¹²Aegerion Pharmaceuticals, Cambridge, MA, USA, ¹³Veristat, Holliston, MA, USA.

STUDY DESIGN

The study design (Figure 1), patient population and overall results for this study have been described previously.¹

Patients underwent a 6-week run-in phase, during which concomitant lipid-lowering therapies, including apheresis, were stabilised. This was followed by a 26-week efficacy phase, which included a lomitapide dose titration period (5–60mg/day based on individual maximum tolerated dose), during which current lipid-lowering therapy and apheresis schedule was kept stable. Patients then entered a 52-week safety phase during which patients remained on their maximal tolerated dose of lomitapide reached in the efficacy phase. During the safety phase, statins and other lipid-lowering therapies (including frequency of apheresis) could be adjusted on a case-by-case basis at the physician and patient’s discretion based on established protocol criteria.
LLTs, lipid-lowering therapies

References